NASDAQ:KALAKala Pharmaceuticals Stock Price, Forecast & News

$12.31

+0.06 (+0.49 %)

(As of 05/29/2020 04:00 PM ET)

Add

Compare

Today's Range

$11.90

Now: $12.31▼

$12.44

50-Day Range

$8.87

MA: $10.85▼

$13.09

52-Week Range

$3.24

Now: $12.31▼

$13.55

Volume894,453 shs

Average Volume1.26 million shs

Market Capitalization$671.79 million

P/E RatioN/A

Dividend YieldN/A

Beta0.26

Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Watertown, Massachusetts.

Beat the Market (BTM) Rank^™

4.5 Analyst's Opinion

Consensus Rating
Kala Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $20.40, Kala Pharmaceuticals has a potential upside of 65.7% from its current price of $12.31.
Amount of Analyst Coverage
Kala Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.6 Community Rank

Outperform Votes
Kala Pharmaceuticals has received 263 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Kala Pharmaceuticals has received 245 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Kala Pharmaceuticals has received 51.77% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Kala Pharmaceuticals and other stocks. Vote “Outperform” if you believe KALA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe KALA will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Kala Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Kala Pharmaceuticals does not have a long track record of dividend growth.

4.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Kala Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $50,057,495.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 30.77% of the stock of Kala Pharmaceuticals is held by insiders.
Percentage Held by Institutions
73.60% of the stock of Kala Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Kala Pharmaceuticals are expected to grow in the coming year, from ($1.76) to ($1.35) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Kala Pharmaceuticals is -4.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Kala Pharmaceuticals is -4.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Kala Pharmaceuticals has a P/B Ratio of 4.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

2.35 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:KALA

Previous Symbol

CUSIPN/A

CIK1479419

Webwww.kalarx.com

Phone781-996-5252

Debt

Debt-to-Equity Ratio0.50

Current Ratio12.17

Quick Ratio11.87

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$6.07 million

Price / Sales110.67

Cash FlowN/A

Price / Cash FlowN/A

Book Value$2.59 per share

Price / Book4.75

Profitability

EPS (Most Recent Fiscal Year)($2.76)

Net Income$-94,350,000.00

Net Margins-1,578.64%

Return on Equity-132.08%

Return on Assets-48.31%

Miscellaneous

Employees136

Outstanding Shares54,573,000

Market Cap$671.79 million

Next Earnings Date8/4/2020 (Estimated)

OptionableOptionable

Receive KALA News and Ratings via Email

Sign-up to receive the latest news and ratings for KALA and its competitors with MarketBeat's FREE daily newsletter.

Kala Pharmaceuticals (NASDAQ:KALA) Frequently Asked Questions

How has Kala Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Kala Pharmaceuticals' stock was trading at $7.63 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, KALA stock has increased by 61.3% and is now trading at $12.31. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Kala Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kala Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Kala Pharmaceuticals.

When is Kala Pharmaceuticals' next earnings date?

Kala Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Kala Pharmaceuticals.

How were Kala Pharmaceuticals' earnings last quarter?

Kala Pharmaceuticals Inc (NASDAQ:KALA) posted its earnings results on Thursday, May, 7th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by $0.03. The business earned $1.07 million during the quarter, compared to the consensus estimate of $2.49 million. Kala Pharmaceuticals had a negative net margin of 1,578.64% and a negative return on equity of 132.08%. View Kala Pharmaceuticals' earnings history.

What price target have analysts set for KALA?

5 brokers have issued twelve-month target prices for Kala Pharmaceuticals' stock. Their forecasts range from $15.00 to $35.00. On average, they expect Kala Pharmaceuticals' stock price to reach $20.40 in the next twelve months. This suggests a possible upside of 65.7% from the stock's current price. View analysts' price targets for Kala Pharmaceuticals.

Has Kala Pharmaceuticals been receiving favorable news coverage?

Media coverage about KALA stock has trended somewhat positive on Friday, InfoTrie reports. The research firm identifies positive and negative news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Kala Pharmaceuticals earned a news sentiment score of 2.0 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news aboutKala Pharmaceuticals.

Who are some of Kala Pharmaceuticals' key competitors?

Some companies that are related to Kala Pharmaceuticals include Alkermes (ALKS), Taro Pharmaceutical Industries (TARO), Amarin (AMRN), Insmed (INSM), Apellis Pharmaceuticals (APLS), Karuna Therapeutics (KRTX), Intercept Pharmaceuticals (ICPT), Turning Point Therapeutics (TPTX), Ra Pharmaceuticals (RARX), Principia Biopharma (PRNB), TG Therapeutics (TGTX), Prestige Consumer Healthcare (PBH), IGM Biosciences (IGMS), Pacira Biosciences (PCRX) and Eidos Therapeutics (EIDX). View all competitors.

What other stocks do shareholders of Kala Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kala Pharmaceuticals investors own include Bristol-Myers Squibb (BMY), Amarin (AMRN), Alibaba Group (BABA), Clovis Oncology (CLVS), Micron Technology (MU), NVIDIA (NVDA), AbbVie (ABBV), Gilead Sciences (GILD), Verastem (VSTM) and Inovio Pharmaceuticals (INO).

Who are Kala Pharmaceuticals' key executives?

Kala Pharmaceuticals' management team includes the following people:

Mr. Mark T. Iwicki, Chairman, Pres & CEO (Age 54, Pay $871.14k)
Mr. Todd Bazemore, Chief Operating Officer (Age 50, Pay $607.5k)
Mr. Eric L. Trachtenberg, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 47, Pay $646.56k)
Dr. Justin Hanes Ph.D., Founder & Chair of the Scientific Advisory Board
Ms. Mary Reumuth CPA, CPA, CFO & Treasurer (Age 45)

When did Kala Pharmaceuticals IPO?

(KALA) raised $90 million in an IPO on Thursday, July 20th 2017. The company issued 6,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Wells Fargo Securities and Wedbush PacGrow were co-managers.

What is Kala Pharmaceuticals' stock symbol?

Kala Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALA."

Who are Kala Pharmaceuticals' major shareholders?

Kala Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include RA Capital Management L.P. (19.93%), Orbimed Advisors LLC (9.90%), Eventide Asset Management LLC (5.41%), BlackRock Inc. (4.10%), Vivo Capital LLC (1.44%) and Driehaus Capital Management LLC (0.92%). Company insiders that own Kala Pharmaceuticals stock include Gregory Grunberg, Howard B Rosen, Ra Capital Healthcare Fund Lp, Rajeev M Shah and Todd Bazemore. View institutional ownership trends for Kala Pharmaceuticals.

Which major investors are selling Kala Pharmaceuticals stock?

KALA stock was sold by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, Alyeska Investment Group L.P., Wedbush Securities Inc., Wells Fargo & Company MN, Morgan Stanley, UBS Group AG, Greenwich Wealth Management LLC, and Legal & General Group Plc. View insider buying and selling activity for Kala Pharmaceuticals.

Which major investors are buying Kala Pharmaceuticals stock?

KALA stock was purchased by a variety of institutional investors in the last quarter, including RA Capital Management L.P., Eventide Asset Management LLC, Orbimed Advisors LLC, Vivo Capital LLC, Driehaus Capital Management LLC, Invesco Ltd., Ensign Peak Advisors Inc, and EAM Investors LLC. Company insiders that have bought Kala Pharmaceuticals stock in the last two years include Gregory Grunberg, Howard B Rosen, Ra Capital Healthcare Fund Lp, Rajeev M Shah, and Todd Bazemore. View insider buying and selling activity for Kala Pharmaceuticals.

How do I buy shares of Kala Pharmaceuticals?

Shares of KALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Kala Pharmaceuticals' stock price today?

One share of KALA stock can currently be purchased for approximately $12.31.

How big of a company is Kala Pharmaceuticals?

Kala Pharmaceuticals has a market capitalization of $671.79 million and generates $6.07 million in revenue each year. The company earns $-94,350,000.00 in net income (profit) each year or ($2.76) on an earnings per share basis. Kala Pharmaceuticals employs 136 workers across the globe.

What is Kala Pharmaceuticals' official website?

The official website for Kala Pharmaceuticals is www.kalarx.com.

How can I contact Kala Pharmaceuticals?

Kala Pharmaceuticals' mailing address is 100 BEAVER STREET SUITE 201, WALTHAM MA, 02472. The company can be reached via phone at 781-996-5252 or via email at [email protected]

This page was last updated on 5/29/2020 by MarketBeat.com Staff